Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features
As Outset has added features improving Tablo since the FDA first cleared it for use, it has now had to submit another 510(k) application to the FDA, thus limiting sales to acute facilities only.
Read the full article » | Posted 07-13-2022
Related Articles
- Vantive Invests $1B in ShareSource Remote Monitoring Posted 06-11-2025
- Apply for the ASN Home Dialysis Scholarship 2025-6 Program by May 31, 2025 Posted 05-20-2025
- Vantive is Supporting ASN’s Centers of Excellence in Home Dialysis Program Posted 05-20-2025
- NKF Spring Clinical Meeting Home Dialysis Posters Posted 04-23-2025